RAPT Therapeutics Appoints Phyllis Loud Gray as Vice President of Human Resources
05 August 2020 - 10:00PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced the appointment of Phyllis
Loud Gray as Vice President of Human Resources.
“Phyllis brings a wealth of expertise and knowledge in
implementing strategies to support a positive and engaging work
environment,” said Brian Wong, M.D., Ph.D., President and CEO of
RAPT Therapeutics. “We are thrilled to have her on board to
navigate our growth and employee development as we anticipate key
readouts for our lead programs, FLX475 and RPT193.”
Ms. Gray brings to RAPT more than 30 years of experience in the
life science and technology industries. She joins RAPT from Sunesis
Pharmaceuticals, where she was Senior Director and Head of Human
Resources, responsible for the development and implementation of
all HR strategies and initiatives. Prior to Sunesis she served as
Senior Director of Human Resources Business at Crescendo
Biosciences, a subsidiary of Myriad Genetics, Inc., where she was a
member of the senior leadership team and responsible for both
strategic and operational direction for human resources. Prior to
Crescendo, she served as Director of Human Resources for
QIAGEN/Ingenuity Systems, VISX, Oracle and Omnicell. She began her
career at Syntex/Syva, serving in various Human Resources roles
over many years. Ms. Gray holds a B.S. in Business Administration
from California State University, Hayward.
“The team at RAPT is passionate, engaged and committed to
delivering new therapeutics for patients who need them,” commented
Ms. Gray. “I’m excited to be a key part of the team that will
diligently maintain the safety and security of our employees
through the COVID-19 pandemic while actively supporting staff
growth and development across the organization.”
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including hematopoietic progenitor kinase 1 (HPK1) and
general control nonderepressible 2 (GCN2), that are in the
discovery stage of development.
Media Contact: Angela Bitting media@rapt.com (925) 202-6211
Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2024 to May 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2023 to May 2024